SCHEMBL12359263

SCHEMBL12359263

CC(O)c1ccccc1-c1ccc2[nH]c(-c3ccc(OCC(F)(F)F)cc3)nc2c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SCD O00767 1/20 0.47
▸ TRPV1 Q8NER1 3/20 0.46
▸ ACHE P22303 2/20 0.44
▸ CHRNB4 P30926 1/20 0.41
▸ CHRNA3 P32297 1/20 0.41
▸ CHRNA7 P36544 1/20 0.41
▸ KDM4E B2RXH2 2/20 0.41
▸ NPC1 O15118 2/20 0.41
▸ ALDH1A1 P00352 2/20 0.41
▸ RAB9A P51151 2/20 0.41
▸ SMN1; SMN2 Q16637 2/20 0.41
▸ USP2 O75604 1/20 0.41
▸ LMNA P02545 1/20 0.41
▸ TP53 P04637 1/20 0.41
▸ MAPT P10636 1/20 0.41
▸ HPGD P15428 1/20 0.41
▸ TSHR P16473 1/20 0.41
▸ NFKB1 P19838 1/20 0.41
▸ NFKB2 Q00653 1/20 0.41
▸ RELA Q04206 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12359221 0.92 SCD (0.44) SCDTRPV1ACHECHRNB4CHRNA3
SCHEMBL1796327 0.86 TRPV1 (0.47) SCDTRPV1CYP17A1CYP2C9CYP2C19
SCHEMBL1800046 0.86 TRPV1 (0.47) SCDTRPV1NPC1RAB9ASMN1; SMN2
SCHEMBL1799740 0.85 TRPV1 (0.66) TRPV1ATP4AATP4B
SCHEMBL1799743 0.85 TRPV1 (0.66) TRPV1ATP4AATP4B
SCHEMBL12359202 0.85 TRPV1 (0.44) SCDTRPV1ACHECHRNB4CHRNA3
SCHEMBL12364472 0.83 TRPV1 (0.47) SCDTRPV1ACHECHRNB4CHRNA3
SCHEMBL1797547 0.83 TRPV1 (0.41) SCDTRPV1ACHEMAPTCYP17A1
SCHEMBL12359203 0.82 TRPV1 (0.46) TRPV1ACHEHDAC3HDAC4HDAC1
SCHEMBL12359266 0.81 SCD (0.42) SCDTRPV1ACHECHRNB4CHRNA3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110190344-A1 BENZIMIDAZOLE MODULATORS OF VR1 JANSSEN PHARMACEUTICA N.V. (BE) 2011-08-04 — — US disclosed
US-7951829-B2 Benzimidazole modulators of VR1 JANSSEN PHARMACEUTICA NV (BE) 2011-05-31 — — US disclosed
US-20070259936-A1 Benzimidazole Modulators of VR1 JANSSEN PHARMACEUTICA N.V. (BE) 2007-11-08 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070259936-A1 Benzimidazole Modulators of VR1 VRK1, VRK2, VIL1 SCD 4754/4885TRPV1 29/4885ACHE 4652/4885
US-20110190344-A1 BENZIMIDAZOLE MODULATORS OF VR1 VRK1, VRK2, VIL1 SCD 4754/4885TRPV1 29/4885ACHE 4652/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback